Single-Arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma (Valemetostat tosylate [DS-3201b], an enhancer of zeste homolog [EZH] 1/2 dual inhibitor, for R/R PTCL)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Daiichi Sankyo Inc
Start Date
April 5, 2022
End Date
March 27, 2027
Administered By
Duke Cancer Institute
Awarded By
Daiichi Sankyo Inc
Start Date
April 5, 2022
End Date
March 27, 2027